May. 14 at 6:39 PM
$IPHA already has strong validation from AstraZeneca, which owns roughly 6 million shares at around a
$6 average and has committed up to
$500M+ in milestone payments tied to one partnered drug alone. With multiple pipeline assets, advancing Phase 3 programs, and growing strategic importance in immuno-oncology, Innate Pharma increasingly looks like a logical long-term acquisition target for AstraZeneca. If the clinical data continues to improve, a full buyout would not be surprising
